This morning we watched Albemarle drop -3.0% to a price of $169.18 per share. The large-cap Chemicals company is now trading -36.49% below its average target price of $266.37. Analysts have set target prices ranging from $155.0 to $344.0 per share for Albemarle, and have given the stock an average rating of buy.
Albemarle has an average level of shares sold short, at 7.5% of its total share float. The stock's short ratio (also called days to cover) is 4.12. The company's insiders own 0.23% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 89.7% of Albemarle's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Albemarle
Date Reported | Holder | Percentage | Shares | Value |
---|---|---|---|---|
2023-06-30 | Vanguard Group Inc | 12% | 14,039,343 | $2,375,105,894 |
2023-06-30 | Blackrock Inc. | 9% | 10,157,015 | $1,718,313,043 |
2023-06-30 | State Street Corporation | 4% | 5,242,800 | $886,950,705 |
2023-06-30 | Bank of America Corporation | 4% | 5,117,596 | $865,769,318 |
2023-06-30 | Capital Research Global Investors | 3% | 3,381,656 | $572,091,664 |
2023-06-30 | Franklin Resources, Inc. | 3% | 3,135,732 | $530,487,470 |
2023-06-30 | Baillie Gifford and Company | 2% | 2,494,230 | $421,961,367 |
2023-06-30 | Geode Capital Management, LLC | 2% | 2,481,901 | $419,875,609 |
2023-06-30 | Capital International Investors | 2% | 2,267,914 | $383,674,357 |
2023-06-30 | Primecap Management Company | 2% | 2,099,025 | $355,102,560 |